Ozempic Shot Costs & GLP-1 Pricing Guide

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) injections cost approximately $900–$1,400 per month at retail without insurance coverage. Most patients rely on copay assistance programs or insurance plans that cover a portion of this cost. Understanding the full pricing landscape—including compounded alternatives—helps ensure informed decision-making about GLP-1 therapy options.

Beyond sticker price, GLP-1 medication selection involves clinical factors like individual metabolic profiles, genetic markers in peptide signaling pathways, and long-term treatment goals. PlexusDx emphasizes precision-wellness approach: matching medication type, formulation, and cost to individual biomarker context, not just comparing price tags alone.

Branded GLP-1 Injection Costs: Ozempic, Wegovy, and Market Pricing

Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight management) are identical active compounds but marketed separately. Ozempic typically costs $900–$1,200 monthly; Wegovy ranges $1,100–$1,400 monthly, though both originate from the same manufacturer. Pricing reflects brand positioning, not chemical difference.

Tirzepatide-based injectables (Mounjaro for diabetes, Zepbound for weight management) cost $1,000–$1,550 monthly at retail. These dual GIP/GLP-1 receptor agonists command premium pricing due to dual-mechanism claims, though real-world efficacy varies significantly by individual response. Insurance formulary placement heavily influences actual out-of-pocket costs.

Medication Pricing Comparison: Branded vs. Compounded Options

Compounded GLP-1 medications from licensed 503A pharmacies offer cost-effective alternatives to branded injectables. Compounded semaglutide ranges $189/mo; compounded tirzepatide spans $289/mo. These formulations contain identical active pharmaceutical ingredients but bypass manufacturer markup and marketing costs.

Medication	Type	Typical Monthly Cost	Key Consideration
Ozempic (semaglutide)	Branded injectable	$900–$1,200	Diabetes indication; often better insurance coverage
Wegovy (semaglutide)	Branded injectable	$1,100–$1,400	Weight management indication; copay assistance available
Mounjaro (tirzepatide)	Branded injectable	$1,000–$1,200	Dual mechanism; limited insurance coverage for weight loss
Zepbound (tirzepatide)	Branded injectable	$1,200–$1,550	Weight management only; newer, less insurance penetration
Compounded semaglutide	Compounded injectable	$149	Licensed 503A pharmacy; requires provider oversight
Compounded tirzepatide	Compounded injectable	$249	Licensed 503A pharmacy; dual GIP/GLP-1 mechanism
Microdose GLP-1 Protocol	Compounded injectable	$129	Lighter starting approach; may suit biomarker-guided tapering
GLP-Squared (dual compound)	Compounded injectable	$249	Custom semaglutide + tirzepatide blend; precision formulation

Insurance Coverage, Prior Authorization, and Copay Assistance Gaps

Insurance coverage for GLP-1 injectables varies dramatically by plan type, indication, and formulary tier. Medicare Part D traditionally excludes weight management; commercial plans increasingly cover Ozempic/Wegovy but often impose prior authorization, step therapy, or BMI thresholds. Copay assistance programs (manufacturer-sponsored) can reduce patient costs to $250–$500/month if approved.

Prior authorization denials and insurance policy changes create significant financial uncertainty. Many patients exhaust appeal processes before accessing branded medications, losing months to administrative delays. Compounded GLP-1 options bypass insurance requirements entirely, providing immediate access without prior auth—a meaningful advantage for time-sensitive clinical situations or coverage gaps.

Biomarker Context and Genetic Factors in GLP-1 Selection and Cost Strategy

GLP-1 medication response varies significantly based on genetic variation in GIPR, MC4R, and FTO genes. A patient with genetic predispositions favoring tirzepatide response may benefit more from a dual-mechanism compounded option than a less costly semaglutide alternative. Biomarker-informed selection can improve clinical outcomes and reduce wasted spending on suboptimal medications.

PlexusDx Precision Peptide Genetic Test ($298) evaluates key variants in peptide signaling pathways—GIPR rs1800437, FTO rs9939609, MC4R rs17782313. These predispositions may help provide context for medication selection and cost-benefit analysis, supporting a more informed conversation with your provider about which formulation and pricing approach aligns with your genetic profile and budget.

Who GLP-1 Therapy Applies To and When Cost-Per-Outcome Matters Most

GLP-1 injectables are indicated for type 2 diabetes (semaglutide, tirzepatide) and chronic weight management in individuals with obesity or overweight plus comorbidities (all formulations). Eligibility requires clinical evaluation; cost-per-outcome analysis should consider long-term cardiovascular benefits, diabetes remission potential, and quality-of-life improvements—not price alone.

Patients experiencing insurance denials, high copays exceeding $500/month, or prior authorization delays often benefit from exploring compounded alternatives through a qualified provider. Compounded formulations offer immediate access, lower out-of-pocket cost, and the same active pharmaceutical ingredient—though treatment oversight and follow-up remain essential regardless of source.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context for GLP-1 medication selection by identifying individual predispositions in peptide signaling pathways. Patients with genetic markers suggesting stronger GLP1R or GIPR sensitivity may respond well to either semaglutide or tirzepatide formulations, while FTO or MC4R variants offer additional metabolic insight. This biomarker framework can inform cost-benefit discussions with providers about whether branded, compounded, or combination approaches align with predicted response likelihood.

The Precision Peptide Genetic Test reveals predispositions in four key GLP-1 pathway variants but does not predict exact medication response or guarantee superior outcomes. Genetic context may help explain why one patient thrives on semaglutide while another experiences better satiety with tirzepatide—even at similar doses. These predispositions should be interpreted with a qualified healthcare provider as one factor among clinical history, comorbidities, and medication tolerability.

Understanding your genetic predispositions in GLP-1 signaling can support a more informed conversation with your provider about medication selection, dosing strategy, and cost optimization. Combined with biomarker data and insurance details, this personalized information helps justify whether premium-priced branded medications, cost-effective compounded options, or combination protocols best fit your clinical profile and budget constraints.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose GLP-1 Protocol is $129/mo flat. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Why do Ozempic and Wegovy carry different price tags if the drug inside is the same?

The article says they are identical active compounds marketed separately, Ozempic for diabetes and Wegovy for weight management, and that the price gap reflects brand positioning rather than any chemical difference. It notes the diabetes indication often means better insurance coverage for Ozempic, while Wegovy is where it flags manufacturer copay assistance as available. Both come from the same manufacturer.

What does insurance typically do with a GLP-1 coverage request?

Coverage varies dramatically by plan type, indication, and formulary tier, per the article. It says Medicare Part D traditionally excludes weight management, while commercial plans increasingly cover semaglutide but often impose prior authorization, step therapy, or BMI thresholds. It describes denials and mid-year policy changes as creating real financial uncertainty, with many patients exhausting appeals and losing months to administrative delay.

What is the practical advantage of a compounded route when a prior authorization stalls?

Speed of access. The article says compounded GLP-1 options bypass insurance requirements entirely and are available without prior authorization, which it calls a meaningful advantage during coverage gaps or time-sensitive clinical situations. It pairs that with the caveat that treatment oversight and follow-up remain essential regardless of source, and that these preparations come from licensed 503A pharmacies.

What does the Microdose GLP-1 Protocol cost through PlexusDx?

The article lists the Microdose GLP-1 Protocol at $129/mo flat, describing it as a lighter starting approach dispensed from licensed 503A compounding pharmacies. It sits among seven prescription GLP-1 protocols the article says are available across all 50 states with no membership and no insurance required, reached through either an async intake or a live consult.

Is the lowest monthly sticker price the right basis for choosing?

The article argues no, reframing the comparison as cost per outcome rather than price alone. It says the analysis should weigh long-term cardiovascular benefits, diabetes remission potential, and quality-of-life improvements, and notes eligibility requires clinical evaluation in the first place. It identifies insurance denials, unaffordable copays, and prior authorization delays as the situations where alternatives merit a look.

Related Reading

• Ozempic Cost 2
• Glp 1 Cost 2
• Eden Glp 1 Cost Plexusdx
• Ozempic Pill Cost

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.